Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44

Both MET exon 14 skipping mutation (METex14SM) and high copy-number variation (CNV) lead to enhanced carcinogenesis; additionally, programmed-death ligand 1 (PD-L1) is often upregulated in cancers. In this study, we characterized the expression of MET (including METex14SM), PD-L1, and CD44 in human...

Full description

Bibliographic Details
Main Authors: Sung-Hwa Sohn, Hee Jung Sul, Bum Jun Kim, Dae Young Zang
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Cancers
Subjects:
c-MET
gastric cancer
tepotinib
Online Access:https://www.mdpi.com/2072-6694/14/14/3444

Internet

https://www.mdpi.com/2072-6694/14/14/3444

Similar Items